Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine + clonidine + meperidine
- Development stage
- Phase 4
- Lead developer
- Tanta University
- Modality
- Small Molecules
- Administration
- Epidural
01
Overview
This drug entry refers to a specific triple-combination analgesic regimen investigated by **Tanta University** for the management of postoperative pain in patients undergoing lower limb orthopedic surgery. The regimen is administered epidurally and consists of the local anesthetic **bupivacaine**, the alpha-2 adrenergic agonist **clonidine**, and the synthetic opioid **meperidine** (also known as pethidine). Bupivacaine provides regional anesthesia by inhibiting voltage-gated sodium channels, thereby blocking nerve impulse conduction. Clonidine acts as an adjuvant that enhances and prolongs the sensory and motor block by stimulating alpha-2 adrenergic receptors in the spinal cord. Meperidine serves as a mu-opioid receptor agonist, providing additional regional and systemic analgesia. Clinical trial data suggests that this combination offers prolonged postoperative analgesia and superior hemodynamic stability compared to similar regimens using fentanyl.
- Other names
- bupivacaine-clonidine-meperidine combinationpethidine + clonidine + bupivacainemeperdine
02
Targets
ADRA2B (α2B)MOR (Mu opioid receptor)ADRA2A (α2A)ADRA2C (α2C)SCN9A (Sodium channel protein type 9 subunit alpha)
Beyond the preview
Go deeper on bupivacaine + clonidine + meperidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine + clonidine + meperidine.